“The Importance of Getting your Children Vaccinated”, new article by Pediatrician Dr. Kenneth Rebong

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong Profile on MedicoGazette

Dr Kenneth Rebong Profile on MedicoGazette

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Office of Dr Kenneth Rebong, San Jose, CA

Office of Dr Kenneth Rebong, San Jose, CA

Kenneth Rebong, MD, doctor in California

Kenneth Rebong, MD, doctor in California

It’s important to get children vaccinated as soon as they are born. This will keep them safe from a plethora of deadly diseases, explains Dr. Kenneth Rebong.

Kenneth Pomar Rebong, MD (N/A:N/A)

Presumably all parents want to keep their children safe. That includes the necessary medical care and vaccinations.”

— Dr. Kenneth P Rebong, pediatrician

SAN JOSE, CALIFORNIA, UNITED STATES, April 16, 2019 /EINPresswire.com/ — It’s important to get children vaccinated to keep them safe from a plethora of potentially deadly diseases. But as always, when in doubt, review the issues with the pediatrician based on the medical history. Presumably all parents want to keep their children safe. That includes the necessary medical care and vaccinations. However, there are controversial and contradictory opinions and information about vaccinations for children. Dr. Kenneth Rebong, MD, based in San Jose, California, provides his thoughts on this issue. The complete article is available on the Blog of Dr. Rebong at https://drkennethrebong.wordpress.com/

Let us start with the basics: What Is a Vaccine?

By now, you probably understand why people are vaccinated. Let’s talk about vaccines in layman terms. A vaccine is a product that is given to children, as well as adults, to protect them from infectious diseases. There are various types of vaccines and every year, developments are made to counteract the effects of new diseases discovered. The chemical components in a vaccine stimulate production of antibodies and provide immunity against various disease processes.

Now here’s the truly fascinating part: the vaccine works due to the causative agent present in the disease, which is used as a synthetic substitute. The antigen induces an immune response in the body without injecting the disease.

So here are the Top 5 Reasons to Get Your Child Vaccinated (and remember that when you are unsure, the child’s pediatrician, based on the available medical history, probably knows best):

1.Get Your Child Vaccinated (usually within first 12 Months) to protect against some diseases

The first vaccination is usually given to a child within the first 12 months (this may differ depending on the particular case, again consult the pediatrician). The basic MMR vaccine protects infants from rubella, measles, and mumps. Another important vaccine that should be given at 2 months is IPV, which protects newborn babies from polio.

Vaccines are given from birth to 18 years. You can check out the schedules and recommended doses at the Centers for Disease Control and Prevention or check with the pediatrician.

2. Vaccines Provide a Shield Against Serious Illnesses

If your child does not get vaccinated at the right time, his or her immune system becomes vulnerable to attacks. When you travel with your children abroad, not only are they at risk but they also put other children at risk.

Some of the vaccine-preventable diseases are:
* Diphtheria
* Hepatitis A
* Haemophilus influenza type b (Caused by bacterial meningitis)
* Hepatitis B
* Influenza
* Human Papillomavirus (Caused by of cervical cancer)
* Measles
* Mumps
* Meningococcal
* Pertussis (Whooping Cough)
* Polio
* Pneumococcal (Causes blood infections and bacterial meningitis)
* Rotavirus
* Tetanus (Lockjaw)
* Rubella (German measles)
* Varicella (Chickenpox)

These diseases can lead to serious complications such as amputation of leg or arm, paralysis of limbs, brain damage, convulsions, and even death.

3. Vaccines Protect Your Child’s Future

Children are exposed to germs on a daily basis. Following are some of the places where your child is likely to come into contact with dangerous bacteria:

* Preschool or daycare
* School
* College
* University
* Doctor’s waiting room
* Community center
* Events and concerts
* Summer camp
* An airplane or a bus

These germs spread through crowded places and by the time you notice the symptoms starting to appear, it may be too late.

4. Vaccines Are Generally Safe

Side effects from vaccines are rarely seen. Consult with your health care professional for more details.

5. Vaccines Save You from Expensive Medical Bills

https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html, which you can refer to, to find out how much your insurance will cover. Remember: get your children vaccinated as their future is at stake here.

About Dr. Kenneth P Rebong

Dr. Kenneth Pomar Rebong, MD, a medical doctor in San Jose, California, and specializes in Pediatrics and Adolescent Medicine. He completed his Pediatric Residency at RUTGERS University in New Brunswick, New Jersey.

https://medicogazette.com/dr-kenneth-pomar-rebong
https://hippocratesguild.com/dr-kenneth-pomar-rebong
https://www.linkedin.com/in/kenneth-pomar-rebong-md-4484a938/

Kenneth Pomar Rebong, MD
Kenneth Pomar Rebong, MD
+1 408-729-3232
email us here
Visit us on social media:
LinkedIn

Will Trump empower vaccine-sceptic parents? BBC News


Source: EIN Presswire

Global Pharmaceutical Drugs And Biologics Logistics Market Growth Rates, Drivers And Restraint

The Business Research Company

The Business Research Company

Pharmaceutical Drugs And Biologics Logistics Market from The Business Research Company, offers a sales Strategy, growth analysis, size, forecast and much more.

LONDON, GREATER LONDON, UK, April 16, 2019 /EINPresswire.com/ — The global pharmaceutical drugs and biologics logistics market grew from around $70 billion in 2013 to nearly $80 billion in 2017 at an annual rate of nearly 4%. The global pharmaceutical drugs and biologics logistics market is expected to grow from around $80 billion in 2017 to above $95 billion in 2021 at an annual rate of almost 5%

Pharmaceutical drugs and biologics logistics covers the physical movement of pharmaceutical and biologic drugs from the manufacturers to the end-users. It includes the transportation, warehousing, inventory management and other logistics functions. The market consists of those pharmaceutical drugs and biologics logistics that are outsourced to logistics companies instead of handled in-house by the pharmaceutical companies.

Growth will result from increasing demand for drugs in general and in particular for temperature-sensitive biopharmaceutical products such as vaccines and blood plasma products. The pharmaceutical drugs and biologics logistics market, has benefitted from the rise in pharmaceutical sales. Governments across the globe are continuously establishing new healthcare reforms triggering the growth of the pharmaceutical market, and urbanization in emerging economies also fuels its growth. The advantages to pharmaceutical manufacturers of outsourcing to logistics service providers are another driver.

Download A Free Sample For The Global Pharmaceutical Drugs And Biologics Logistics Market At:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2315&type=smp

Factors that could hinder the growth of the global pharmaceutical drugs and biologics logistics market include poor infrastructure for cold chain logistics, skills shortages in the industry and unstable regulatory environments in emerging countries. The market may also be negatively affected by increased regulation on temperature-sensitive pharmaceutical products distribution.

Pharmaceutical Drugs And Biologics Logistics Market Global Opportunities And Strategies To 2021 is one of a series of new reports from The Business Research Company that provides pharmaceutical drugs and biologics logistics market overviews, analyzes and forecasts pharmaceutical drugs and biologics logistics market size and growth for the global pharmaceutical drugs and biologics logistics market, pharmaceutical drugs and biologics logistics market share, pharmaceutical drugs and biologics logistics market players, pharmaceutical drugs and biologics logistics market size, pharmaceutical drugs and biologics logistics market segments and geographies, pharmaceutical drugs and biologics logistics market trends, pharmaceutical drugs and biologics logistics market drivers and pharmaceutical drugs and biologics logistics market restraints, pharmaceutical drugs and biologics logistics market’s leading competitors’ revenues, profiles and market shares. The pharmaceutical drugs and biologics logistics market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Where To Learn More

Read Global Pharmaceutical Drugs And Biologics Logistics Market Opportunities And Strategies To 2021 from The Business Research Company, for information on the following:

Markets Covered: Global pharmaceutical drugs and biologics logistics market, (type of service – non-cold chain logistics market, cold chain logistics market); mode of transport- (air transportation market, ocean transportation market, land transportation market); pharmaceutical type- (pharmaceutical drugs logistics market, biologics logistics); therapeutic area- (musculoskeletal market, cardiovascular market, oncology market, anti-infective market, metabolic disorders market, central nervous system market, genito-urinary market, respiratory market, gastro-intestinal market, hematology market, dermatology market, ophthalmology market)

Data Segmentations: pharmaceutical drugs and biologics logistics market size, global and by country; historic and forecast size, and growth rates for the world, 7 regions and 12 countries; by type of service segments – ((type of service – non-cold chain logistics market, cold chain logistics market); mode of transport- (air transportation market, ocean transportation market, land transportation market); pharmaceutical type- (pharmaceutical drugs logistics market, biologics logistics); therapeutic area- (musculoskeletal market, cardiovascular market, oncology market, anti-infective market, metabolic disorders market, central nervous system market, genito-urinary market, respiratory market, gastro-intestinal market, hematology market, dermatology market, ophthalmology market)) market size, historic and forecast size, and growth rates for the world, 7 regions and 12 countries.

Pharmaceutical Drugs And Biologics Logistics Market Organizations Covered: Deutsche Post DHL, FedEx Corporation, Panalpina World Transport, UPS, Kuehne + Nagel and DB Schenker.

Regions: North America, Western Europe, Asia-Pacific, South America, Eastern Europe, Middle East and Africa.

Time Series: Five years historic (2013-17) and forecast (2017-21).

Other Information And Analyses:, Global pharmaceutical drugs and biologics logistics market comparison with macro-economic factors, pharmaceutical drugs and biologics logistics market size, percentage of GDP, global, by country, per capita average pharmaceutical drugs and biologics logistics expenditure, global, and by country, PESTEL analysis, pharmaceutical drugs and biologics logistics market competitive landscape and company profiles, pharmaceutical logistics market product analysis, pharmaceutical logistics market trends and opportunities, drivers and restraints, key mergers and acquisitions.

Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes.

Strategies For Participants In The Pharmaceutical Drugs And Biologics Logistics Industry: The report explains over 13 strategies for companies in the pharmaceutical drugs and biologics logistics market, based on industry trends and company analysis. These include large pharmaceutical logistics companies focusing on acquiring new technologies and expertise of small market players to expand their geographical presence and gain market share, and DHL Express’ strategy aiming at further expansion of services for the e-commerce market and supply chain market.

Opportunities For Companies In The Pharmaceutical Drugs And Biologics Logistics Sector: The report reveals where the global pharmaceutical drugs and biologics logistics industry will put on most $ sales up to 2021.

Number of Pages: 294
Number of Figures: 178
Number of Tables: 177

Interested to know more about The Business Research Company?

The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. Here is a list of reports from The Business Research Company similar to Pharmaceutical Drugs And Biologics Logistics Global Market Opportunities And Strategies To 2021(https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market)

Pharmaceutical Drugs Market Global Opportunities And Strategies To 2021(https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-market)

Blood Glucose Test Strips Market Global Opportunities And Strategies To 2021(https://www.thebusinessresearchcompany.com/report/blood-glucose-test-strips-market)

Healthcare Analytics Market Global Opportunities And Strategies To 2022(https://www.thebusinessresearchcompany.com/report/healthcare-analytics-market)

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Aspect Furniture supply Pfizer with Office Furniture for Sydney office fitout

Pfizer Australia, one of the world's leading biopharmaceutical companies, has relocated its Australian office into a new building in the heart of Sydney CBD.

SYDNEY, NEW SOUTH WALES, AUSTRALIA, April 16, 2019 /EINPresswire.com/ — Pfizer Australia, one of the world's leading biopharmaceutical companies, has relocated its Australian office into a new building in the heart of the Sydney CBD. The building – Barrack Place, at 151 Clarence St, is one of the most advanced buildings in its class in Sydney.

Pfizer occupies the top four floors of this new prestigious building in an emerging entrepreneurial and innovation hub. The immediate business precinct is where many innovative businesses have set up such as Atlassian and Apple.
Aspect Furniture worked with Siren Design on Pfizer’s new 4640m2 head office based in the Sydney CBD at Barrack Place.
Relocating from a very traditional office in suburban West Ryde to a state-of-the-art building in the heart of the CBD, Pfizer have created a truly agile and contemporary environment. Customised electric sit to stand workstations are intermixed with private focus booths and a range of settings for collaboration.

Meeting spaces were carefully considered to enable technology integration and our Agility system was used across many of the flexible spaces. This was supplemented by a number of sit to stand tables – including a large format 3800 x 1600mm video conferencing table.

Aspect worked closely with the project manager Pepper and builder MPA to deliver well within programme. For more information or to arrange an appointment at the nearby Aspect Sydney showroom in Level 1 40 King Street, please call Grant Kennerley on 0437 352 175.

Grant Kennerley
Aspect Furniture Pty
+61299292200
email us here


Source: EIN Presswire

CCHR Documentary Exposes Psychiatric Profit Driven Mental Illness Strategy

Marketing of Madness Label

The headquarters for CCHR Florida are located in downtown Clearwater.

The headquarters for CCHR Florida are located in downtown Clearwater.

The Citizens Commission on Human Rights is a non-profit mental health watchdog dedicated to the eradication of abuses committed under the guise of mental health.

The Citizens Commission on Human Rights is a non-profit mental health watchdog dedicated to the eradication of abuses committed under the guise of mental health.

The documentary reveals the true insanity in our psychiatric health care system – profit-drive marketing at the expense of patients, families and communities.

This documentary is detailing how the psychiatric industry is attempting to penetrate into nearly every aspect of American life.”

— Citizens Commission on Human Rights

CLEARWATER, FLORIDA, UNITED STATES, April 16, 2019 /EINPresswire.com/ — The Marketing of Madness is a closely researched film that documents a growing psychiatric strategy to label children and adults with mental disorders, which lack any medical basis of diagnosis, and to place them on powerful psychiatric drugs that are often addictive and have dangerous side effects.

Exposing the questionable ethics of the psychiatric profession's close marketing ties with pharmaceutical corporations, the documentary reveals the true insanity in our psychiatric health care system – profit-drive marketing at the expense of patients, families and communities.

The National Institute of Mental Health asserts that tens of millions of people in the USA alone have mental illnesses and that the number has been constantly growing for decades. This mysterious modern-day plague is explained by the profits generated by a “diagnosis” of mental illness lacking any physical test. The more that are diagnosed, the more profit for pharmaceutical supply chains and for psychiatrists who promote and prescribe these habit-forming drugs.

Additionally, the rationale that “he shot those school children because he had a mental illness” is exposed by this documentary as a red herring designed to focus attention away from the real cause of sudden and unexplained violence – psychiatric drugs with homicidal and suicidal side effects.

There is growing evidence of the link between psychotropic drugs prescribed to children, and epidemics of school violence. Seven out of the ten drugs linked to violence are either anti-depressants or ADHD drugs. Prescribing those labeled as mentally ill with hazardous drugs sends the disturbing message that commercial profits are more important than the safety of children and families. [1]

The Citizens Commission on Human Rights of Florida (CCHR), announced recently that they will be hosting a showing of the psychiatric documentary, The Marketing of Madness, in their downtown facility. The full-screen showing will be presented to visitors at no charge. To find out when the next screening of The Marketing of Madness will be held, please call CCHR at (727) 442-8820.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. L. Ron Hubbard, founder of Scientology, first brought psychiatric imprisonment to wide public notice: “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health,’” he wrote in March 1969.

Sources:

[1] Psychiatric Drugs: Create Violence & Suicide https://www.cchrint.org/pdfs/violence-report.pdf

Diane Stein
Citizens Commission on Human Rights of Florida
(727) 422-8820
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

The Marketing of Madness CCHR Drug Documentary – Are We All Insane? (Trailer)


Source: EIN Presswire

Advanced Structural Insulation Market Status and Global Forecast, by Players, Types and Applications 2019-2024

Advanced Structural Insulation -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

PUNE, MAHARASHTRA, INDIA, April 16, 2019 /EINPresswire.com/ — Advanced Structural Insulation Industry

Description

Wiseguyreports.Com Adds “Advanced Structural Insulation -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database

In today’s market, residential and commercial builders are faced with myriad options for improving building energy efficiency including high-performance insulation, energy efficient equipment, and a growing cadre of smart systems and controls. When seeking green building certification or simply higher energy efficiency construction, cost effectiveness and multiple benefits become critical factors in selecting energy efficient, green technologies. Structural insulation includes a group of rapidly growing, multibenefit residential and commercial building technologies designed to greatly improve insulation capacity while also advancing building strength and providing several other important benefits, including reduced installation cost, exceptionally fast framing, reduced weight, disaster resistance, and reduced sound penetration.

Even with its strong benefits, structural insulation—including structural insulated panels (SIPs), insulated concrete forms (ICFs), insulated concrete blocks/concrete masonry units, and insulated concrete—global insulation markets carry much opportunity for growth, development and increased market penetration by structural insulation. The technologies face a building industry that is at once hungry for cost saving, time saving, and green building systems, but that also cautiously resists change. Some technologies, such as insulated concrete blocks/masonry units carry a strong advantage, in that they are nearly dropin replacements for existing building technologies. This greatly lowers risk and limits the need for extensive worker training and expertise. In contrast, SIPs and especially ICFs require skilled, experienced installers to ensure proper application. Many regions are approaching a critical mass of such skilled labor, but others lag behind, slowing market development. This study seeks to characterize these and other key market headwinds and drivers, identify technologies and applications that are leading structural insulation development and market penetration, and provide carefully benchmarked, reliable data on market valuations in the structural insulation industry through 2023.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3904018-advanced-structural-insulation-global-markets-to-2023

Data on market splits within commercial buildings have been historically very difficult and costly to identify. This report, however, has a significant and unique benefit of providing detailed market breakdowns by a total of seven commercial building categories, including commercial office buildings, retail, education, healthcare, hotels and restaurants, institutional and assembly buildings, and warehouses and storage. Additionally, markets are also broken down by technology, including SIPs: polystyrene (EPS or XPS) insulation; SIPs: polyurethane or polyisocyanurate insulation; SIPs: other insulation material; ICFs: polystyrene (EPS or XPS) insulation; ICFs: other insulation; insulated concrete 
blocks; and insulated concrete. Along with detailed splits by region and by key countries/major economies, the project provides deep insight to corporations and other market players seeking to make critical business decisions.

The following table and figure present market values for aggregated application categories. The structural insulated panels (SIPs) and insulated concrete forms (ICFs) market segment includes the following individual technologies: SIPs with polystyrene (expanded polystyrene [EPS] or extruded polystyrene [XPS]) insulation, SIPs with polyurethane or polyisocyanurate insulation, SIPs with other insulation, ICFs with polystyrene (EPS or XPS) insulation, and ICFs with other insulation. The insulated concrete and insulated concrete blocks category includes insulated concrete based on all relevant insulating materials, and insulated concrete blocks (i.e., insulated concrete masonry units [CMUs]).

Report Scope:

This study reviews key structural insulation technology categories, along with relevant market and production information, technological descriptions and issues, applications, and market factors and potential, and gives an overview of relevant incentives and regulations in major worldwide markets. This study will be of interest to current and potential manufacturers and suppliers of residential and commercial structural insulation manufacturers, and entrepreneurs and entrepreneurial companies interested in entering or expanding into the structural insulation sector.

The market analysis provided in this report is based on a variety of data sources. These include the most recent government, industry, and corporate data on structural insulation sales, production, imports, and exports; manufacturing rates and detailed commercial building trends used to help gauge historic and anticipated future market growth; data generated by recent and ongoing research and development efforts aimed at identifying new and developing niches for certain classes of structural insulation, and potential for associated growth; and available corporate announcements for keystone industry developments, new products and successes.

Leave a Query @ https://www.wiseguyreports.com/enquiry/3904018-advanced-structural-insulation-global-markets-to-2023

Structural insulation technology carries the potential to be game-changing within the industry. The technology is able to support increased energy efficiency, reduced amount of construction material (and therefore reduced cost), and in many cases easier installation, which itself helps to reduce construction labor costs associated with installation of conventional insulation systems. Thanks to increases in R&D and granted associated patents in recent years, new structural insulation technologies are expected to become commercially viable within the next five years. In this report, BCC Research analyzes each major viable structural insulation material and application, determines current market status, examines impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are assessed and discussed, as are the current and likely industry trends and updates. Sales of both new and replacement/retrofit structural insulation systems are considered.

BCC Research analyzes the structural insulation industry on a worldwide basis in terms of its manufacturing and the deployment of its technologies or products. BCC Research also examines key market drivers and headwinds and their roles in driving or throttling the global structural insulation market worldwide.

Report Includes:

– 68 data tables and 47 additional tables 
– An overview of the global markets for advanced structural insulation 
– Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 
– Segmentation of the market by technology, end-users, application, and region 
– Examination of the market dynamics and industry structure, specifically market drivers and opportunities in the global advanced structural insulation market 
– Information on current and emerging end-users of advanced insulation, including commercial and residential buildings 
– Relevant patent analysis 
– Company profiles of major players in the market, including Knauf, Nova Chemicals, Owens Corning, Rockwool and Shelter Enterprises, Inc.

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3904018

Continued…

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Global Neurophotonics Market 2019 Share, Trend, Segmentation And Forecast To 2024

Neurophotonics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

PUNE, MAHARASHTRA, INDIA, April 16, 2019 /EINPresswire.com/ — Neurophotonics Industry

Description

Wiseguyreports.Com Adds “Neurophotonics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database

Optical technologies are gaining increasing popularity in the biomedical field for evaluating and treating a range of medical conditions. During the past 50 years, optical technologies have also been introduced into the study of neurons and neural activities, contributing to the expansion of a new branch of biophotonics and neuroscience called neurophotonics. Light-based technologies are gaining growing interest in neurology because they offer advantages over other methods (e.g., X-rays, magnetic fields and radio waves), such as lower cost, long-term safety and portability.

BCC Research has identified three fields of application where neurophotonic technologies have current and potential use: research, diagnosis and therapy. Equipment for research and diagnosis primarily consists of imaging instruments, whereas systems for therapy are mainly used for neurostimulation and biomodulation.

This report provides a comprehensive description of neurophotonic systems and their characteristics, highlighting the latest developments in their fabrication technology and features. It also offers a detailed market analysis for these products by segment (system type, application, neurological condition and region), describing technical aspects and trends that will affect the future growth of this market. As shown in the Summary Table, the global market for neurophotonics increased from REDACTED in 2016 to REDACTED in 2017 and is estimated to be valued at REDACTED in 2018.

The increasing prevalence of neurological disorders, especially age-related and developmental conditions, the search for state-of-the art diagnostic techniques, and the need to provide better healthcare to a population that is growing older worldwide, are the main drivers for this growth, which corresponds to a healthy CAGR of REDACTED during the period of 2016 through 2018.

With estimated revenues of REDACTED, imaging equipment currently accounts for REDACTED of the total market. These systems consist of microscopy, spectroscopy and multimodal equipment, as well as instruments that can detect photosensitive materials genetically incorporated in animal cells. By comparison, light-based systems for therapy currently represent a much smaller share of the market at REDACTED of the total, corresponding to estimated 2018 revenues of REDACTED.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3904029-neurophotonics-global-markets-and-technologies-to-2023

Report Scope:

This report provides an updated review of neurophotonics technologies, including a description of various devices, and identifies current and emerging technologies used in different neurology fields.

BCC Research delineates the current market status for these products, defines trends and presents growth forecasts for the next five years. The neurophotonics market is based on four segments: system type, application, neurological disorder and region. In addition, technological issues, including key events and the latest developments, are discussed.

More specifically, the market analysis conducted by BCC Research for this report appears over five chapters.

Chapter 3 of the report introduces the topic and a historical review of neurophotonic technologies, including an outline of recent events. This chapter identifies the main neurological conditions that are currently being evaluated or treated using these systems.

Chapter 4 provides a technological review of various types of optical systems for neurophotonics, together with their primary features and uses. This chapter concludes with an analysis of the most important technological developments since 2016, including examples of significant patents recently issued or applied. The chapter ends by listing the most active research organizations operating in this field and their activities.

Chapter 5 entails a global market analysis of neurophotonics technologies. Global revenues (sales data in millions of dollars) are presented for each segment (system type, application, neurological condition and region), with actual data for 2016 and 2017 and estimates for 2018. Dollar figures refer to sales of these systems at the manufacturing level.

The analysis of current revenues for neurophotonics technologies is followed by a detailed presentation of market growth trends, based on industry growth, technological trends and regional trends. The third section concludes by providing projected revenues for optical systems used in neurophotonics within each segment, together with forecast compound annual growth rates (CAGRs) for the period of 2018 through 2023. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.

Chapter 6, which covers global industry structure, lists the leading manufacturers of neurophotonics systems, along with a description of their products. The analysis provides the geographical distribution of these firms and an evaluation of other key industry players. Company profiles of the top players are also provided.

Chapter 7 includes an analysis of recently issued U.S. patents, with a summary of patents related to fabrication processes, methods for using neurophotonic systems and applications. Patent analysis is performed by region, country, assignee, patent category, system type and application.

Report Includes:

– 55 data tables and 20 additional tables 
– A detailed overview of technologies and markets for neurophotonics within the industry 
– Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023 
– Identification of important technology and industry trends within each market segment 
– Information on new technological developments related to neurophotonic systems, while outlining current technical issues 
– Description of the most relevant R&D activities and examination of trends in recently issued U.S. patents 
– Company profiles of the leading market players, including Bruker Scientific, Carl Zeiss, Hitachi, Horiba, Leica Microsystems and Thermo Fisher Scientific

Leave a Query @ https://www.wiseguyreports.com/enquiry/3904029-neurophotonics-global-markets-and-technologies-to-2023

Table of Contents 

Chapter 1 Introduction 
Chapter 2 Summary and Highlights 
Chapter 3 Market and Technology Background 
Chapter 4 Technology 
Chapter 5 Global Markets 

Chapter 6 Global Industry Structure and Company Profiles 
Leading Manufacturers of Optical Technologies for Neurophotonics 
Distribution of Leading Suppliers, by Technology Type and Region 
Other Industry Players 
Company Profiles 
ARTINIS MEDICAL SYSTEMS 
BRUKER SCIENTIFIC 
CAIRN RESEARCH 
CARL ZEISS 
FEMTONICS 
FNIR DEVICES 
HEMOPHOTONICS 
HITACHI 
HORIBA 
INTELLIGENT IMAGING INNOVATIONS 
ISS 
LEICA MICROSYSTEMS 
NANOSCOPE TECHNOLOGIES 
Nikon 
NIRX 
Olympus 
PERKINELMER 
SCIENTIFICA 
THERMO FISHER SCIENTIFIC 
VIELIGHT 

Chapter 7 Patent Analysis 

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3904029

Continued…                       

 

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Is it Hemp – Is it Marijuana- Is it Recreational – Is it Medical – What is it all about?

Testing forTHC,CBD, CBG ,CBN in cannabis products

Testing cannabinoids in Hemp and Cannabis products and plant material

THC, CBD testing charts

Potency and finger print charts

Cannabis-Hemp  Certified test kits, complete  mini lab

Complete mini lab all you need to strat a small TLC lab includes 80-100 test

You need to know what is Hemp in order to Benefit your Life and your Wallet

MEFORD, OR, U.S.A., April 16, 2019 /EINPresswire.com/ — Let’s start with, what is it Marijuana or Hemp? well the current USA laws would like you to believe that Hemp is NOT a type of Marijuana plant but instead an industrial, medical farm plant that before this year was as federally illegal as a THC based Marijuana plant which is still a federally illegal narcotic, Class 1. Now the federal government has decided that a Hemp plant is a legal Farm Crop and is no longer part of any type of drug laws and is now equal to farming a potato, managed by the FDA NOT the DEA.

The reality is that Hemp is Marijuana with a lot less THC originally produced in the plant were” Marijuana” has normally a lot more natural THC which to this date is the only cannabinoid illegal in Marijuana, and also the only one presently known that can give psycho-active results, like eating the wrong type of mushroom were psilocybin is the psycho active ingredient in some but not others.

There are at least 40-70 protentional medical cannabinoids in a marijuana plant and around 140 cannabinoids all together in one plant, so which plant will come out as the leader, I believe neither. They are both the same DNA structure and even the DEA cannot come up with a filed test to tell the difference between a Marijuana plant and a Hemp plant, so the logical conclusion will be that both will become seen as one (for many different reasons) so laws can become consistent throughout the USA at some point.

Benefits of both plants:

Hemp Plants is a marijuana plant that naturally produces a very small amount of THC, since the plant creates its own balance of cannabinoids, if you have a higher CBD content then you will have a lower THC content in the plant, so for CBD product producers and manufactures starting with a plant that has very little THC is a big + Since most states currently require less than 1% THC in any CBD products currently produced. The seeds from the plant are crushed along with any tri-cones that can be harvested from the plant and the oils used for everything form medicines to hand creams with a lot more in between.

The Hemp plant was grown by the US government for years to produce clothing but mostly for making large ropes that ships used to tie down to harbor docks and was grown until the early 60’s when polyester rope was created and replaced all the commercial rope products. Currently the CBD medicines are proving to be real health aids.

We at TLC Lab Supply have been selling TLC testing kits and supplies for over 10 years and the feedback from the CBD and THC products that are tested with our kits has been consistent and always show very positive results for the clients and producers we hear from. The amount of CBD in a product varies there are no standards for any CBD products other than no THC (in them which is in my opinion in some medicines is needed in conjunction with the CBD but that is another topic). But testing your products to determine potency and consistent results will be the bases for many products, we supply those testing products with our kits if you have less than 1% THC you will get a blank spot were the THC marker would be seen.

Marijuana Plants

To start with, this plant cannot make up its mind if it is a girl or a boy until over ½ way through its growing period ( how many plants do you know that work like that) that is one of the reasons that clones ( from a female cannabis plant) were created to insure that you get an already started female plant rather than start with a seed, which with a normal seed, you would have to wait weeks to determine if it was a female which is what people that want high THC will need. Normally you will also know what type of plant you are going to have (Indica or Sativa) and that it will be a girl.

Fact: TESTING OF ANY CANNABIS PRODUCTS IS A MUST!

All states and most legal countries require testing to determine either the high THC content for consistent results of THC based products or for legal CBD products you must have less the 1% THC to be a legal CBD product so you must test to make sure you have less the 1% and you must also test for the potency of THC and CBD in all cannabis products. There are labs, all with Gas Chromatography (GC), Liquid Chromatography (HPLC) (which have no legal testing standards because the federal government has not created any yet) and Thin Layer Chromatography, (TLC). These are the 3 most common used testing methods for cannabis (go here for independent study of all 3 types of testing)- https://www.thctestkits.com/3labtesting/).

Current California testing laws suggest using TLC testing for most of their products.

TLC Lab Supply has been selling Certified THC, CBD, CBG and CBN testing kits and supplies for testing cannabis plant material and products made from plant material from Marijuana and Hemp worldwide. They give consistent results and accuracy, are very easy to use and extremely affordable. For a ton of information, an instructional video and our online store go to: https://www.thctestkits.com/

Hemp based products are currently on retail shelfs in Hawaii and are advertised to be in CVS and Walgreens Pharmacy, soon they will be everywhere, if you are a product producer or in the cannabis industry you will need to be ready for a great opportunity to get your products on the retail shelves of many different types of outlets in the next year. So be ready, test your products for accuracy in potency and consistency for your product production.

Roger Green
R Green Services/ TLC Lab Supply
5416901000
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn

Instructional video using our testing kits – easy to use, consistent results


Source: EIN Presswire

CVR Medical Announces Prospective Collaboration with Canon Financial Services for Leasing of Carotid Stenotic Scan (CSS)

Canon Financial Services Poised to Provide CSS Device Leasing Solutions to CVR Medical’s Anticipated Global Customer Base

CVR Medical Corp. (OTCQB:CRRVF)

DENVER, NC, USA, April 15, 2019 /EINPresswire.com/ — CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical”), a Canadian-listed and US-based healthcare company in the medical device sector, announced that it is currently in negotiations with Canon Financial Services, Inc. (CFS), a wholly owned subsidiary of Canon U.S.A., Inc., to provide leasing services for CVR Medical’s Carotid Stenotic Scan (CSS) line of products to the healthcare market. This agreement will expand the relationship between CVR and the Canon group company, Canon Virginia, Inc., which is currently contracted for the manufacturing of the CSS.

The arrangement with CFS would represent an important step in CVR Medical’s progress toward increasing the accessibility of early-stage care for vascular disease. With best-in-class services for end-user financing solutions and the global strength of the Canon brand, a broad spectrum of clinical professionals, including primary care physicians, would be able to incorporate the CSS into their everyday practices with confidence and financial flexibility.

Peter Bakema, CVR Medical’s Chief Executive Officer, states, “We believe that the future of vascular care lies in the highly-accurate, non-invasive, diagnostic technique that the CSS is designed to offer. It is our intention to not only provide value for large institutional medical providers, but also to make our technology available to office-based clinicians. We are proud to expand our relationship with Canon. We feel that this new financial collaboration will help to significantly increase the CSS’s market entry potential once FDA approval is received and simultaneously enhance the financial strength of our organization.”

“As a true captive leasing company our goal is to provide best in class products and services to our Canon family of products”, stated Dominic Janney Vice President of Sales and Servicing for CFS. We are honored to have been selected by CVR Medical to not only assist with a solution which will lower the total cost of ownership of their product, but to also be a partner in their journey. We look forward to this exciting new opportunity and creating products and programs that will address the changing needs of the customers through innovation and best in class service.

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its potentially disruptive, proprietary Carotid Stenotic Scan (CSS). The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in clinical trials at several research institutions and has submitted its CSS device to the FDA as a De Novo application. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

About Canon Financial Services, Inc.

As part of Canon, Inc. (NYSE:CAJ), a leader in digital imaging solutions, Canon Financial Services, Inc. (CFS) offers end-user financing through term leases and financing arrangements for healthcare equipment, software and related systems across the U.S. CFS provides co-branded lease documents, efficient processes, competitive pricing, and special promotions and programs designed to sell products and services in the healthcare market

About Canon U.S.A., Inc.

Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean markets. With approximately $36 billion in global revenue, its parent company, Canon Inc. (NYSE:CAJ), ranks third overall in U.S. patents granted in 2018 and is one of Fortune Magazine's World's Most Admired Companies in 2018. Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. To keep apprised of the latest news from Canon U.S.A., sign up for the Company's RSS news feed by visiting www.usa.canon.com/rss and follow us on Twitter@CanonUSA.

ON BEHALF OF THE BOARD:

(signed) "Peter Bakema"
CEO, President & Director

For further information contact:

CVR Medical Corp.
Peter Bakema, CEO, President and Director
Email: info@cvrmed.com
or
Marc S. Lubow.
Executive Vice President
(904) 923 – 4037
marclubow@cvrmed.com

Canon Financial Services, Inc.
Contact: Paul Hackett, Sr. Healthcare Relationship Mgr.
Email: phackett@cfs.canon.com
or
Healthapps@cfs.canon.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to our CSS device and our partnership with Canon. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with the development and commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the CSS device, (5) the risk that the Company does not execute its business plan or that the companies engaged to develop and obtain regulatory approval for the CSS device do not execute their plans, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Marc Lubow
CVR Medical Corp.
+1 904-923-4037
email us here


Source: EIN Presswire

UV-C Disinfection Found to Successfully Prevent Transmission of Superbug, Candida auris

WAUKESHA, WI, UNITED STATES, April 15, 2019 /EINPresswire.com/ — FOR IMMEDIATE RELEASE

UV-C Disinfection Found to Successfully Prevent Transmission of Superbug, Candida auris

WAUKESHA, Wis. (April 15, 2019) – As serious concerns about the superbug Candida auris (C. auris) continue to grow and national media turns its focus towards the deadly impact, a study from the University of Chicago Medicine found that the use of the Surfacide Helios® UV-C Disinfection System, along with standard terminal cleaning, was an effective and reliable strategy to address this potentially deadly fungal disease from the environment(1).

According to the Centers for Disease Control and Prevention (CDC), approximately 617 people across the U.S. have already been infected by the fungus. The CDC warns that the spread of this drug-resistant fungus poses a serious global health threat – especially for older and immune-compromised patients.

“Hospitals across the U.S. are coming to terms with the severity of Candida auris and are looking for the best possible way to prevent transmission,” said Adam Buchaklian, PhD. and director of clinical research for Surfacide. “The Surfacide Helios® UV-C Disinfection System is effective against the fungus and we are working with hospitals systems around the country to educate and help prevent it from spreading.”

Surfacide’s Helios system incorporates three UV-C energy emitting towers in the patient environment to address the presence of organisms including: C. auris, C. Diff, MRSA, VRE, CRE and Acinetobacter. The system has been shown in studies to significantly reduce the risk of HAIs while lowering hospital infection rates.

“The emergence of C. auris highlights the vigilance that healthcare leaders must focus upon daily in their effort to stay ahead of MDROs like C. auris. As a result, many healthcare leaders are proactively looking for solutions in anticipation that this C. auris will emerge in other regions of the country,” said Gunner Lyslo, Surfacide, Founder & Chief Executive Officer. “Given our experience in addressing C. auris within the University of Chicago Medical Center and Mount Sinai Brooklyn, we are in a unique position to assist other healthcare facilities.”

Surfacide, is the only system that addresses the impact of shadows and distance. It is typically able to deliver an effective dose of energy in approximately 10 to 20-minutes in an unoccupied room, after an environmental services cleaning professional has manually cleaned the area. Treating the room with UV-C energy is an evidence-based disinfection modality, disinfecting areas that were not completely cleaned manually.

The Surfacide Helios system is available in the U.S. and internationally. For more information as well as efficacy studies, visit surfacide.com or call 844-390-3538.

About Surfacide
Surfacide provides an evidence-based, automatic UV-C room disinfection system that addresses multi-drug resistant organisms, including C. auris, C. Diff, MRSA, VRE, CRE and Acinetobacter. The Surfacide Helios® system implements three emitters into the patient environment to clean all areas of the patient room, including the bathroom and other hard-to-reach areas.

###

1. Rachel Marrs, MSN, RN, CIC1, Daniela Pellegrini, MD2, Aurea Enriquez, M(ASCP), CIC1, Jessica P. Ridgway, MD, MS3 and Emily Landon M. Successful Environmental Disinfection to Prevention Transmission of Candida Auris. IDweek 2017. San Diego: IDweek 2017; 2017. p. 495.

Kristin Paltzer
Surfacide
+1 414-316-2100
email us here


Source: EIN Presswire

Hawthorne Pharmacy Announces New Store Opening

Hawthorne Pelion Pharmacy Officially Opens April 1

PELION, SC, UNITED STATES, April 15, 2019 /EINPresswire.com/ — Pelion, SC: Hawthorne Pharmacy & Medical Equipment is proud to welcome Hawthorne Pelion Pharmacy to the Hawthorne family. As Hawthorne Pharmacy celebrates their 70th Anniversary, they are excited to open another store and expand Hawthorne Pharmacy and Medical Equipment. Hawthorne Pelion Pharmacy will be officially opening April 1, 2019. The new pharmacy is located at 8073 Edmund Hwy., Pelion, SC 29123. Hawthorne Pelion Pharmacy can be reached by phone, 803-894-4010.

Kristie Cassidy, Pharmacist, expresses, “We are so delighted to welcome another store location to the Hawthorne family. It has been a pleasure to serve the community for the past 70 years and we look forward to now serving the Pelion community.” Hawthorne Pharmacy & Medical Equipment proudly provides medication and medical equipment to the citizens of South Carolina. Everyone deserves the best quality care and attention. With the 7 locations and the addition of this new store location, Hawthorne Pharmacy will continue to provide medication and superior information every step of the way.

Hawthorne Pharmacy provides compounding, medical equipment, prescription refills, seminars and, top notch customer service. For any questions, please visit our website.

Kim Cannan
Hawthorne Pharmacy
+1 803-227-4468
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire